METHODS, SYSTEMS, AND COMPOSITIONS FOR PREDICTING RESPONSE TO IMMUNE ONCOLOGY THERAPIES

1 . A method of selecting a subject for treatment with an immune oncology (IO) therapy, wherein the subject is in need of treatment for a cancer, the method comprising:

at a computer system having one or more processors, and memory storing one or more programs for execution by the one or more processors:

applying, by the one or more processors, one or more model components derived from sequencing data from a sample of the cancer to one or more machine learning algorithms (MLAs), wherein the sequencing data comprises RNA sequencing data and DNA sequencing data, wherein the one or more model components comprise a tumor mutational burden (TMB), a checkpoint related gene signature, an immune exhaustion signature, a granulocytic myeloid derived suppressor cell (gMDSC) signature, and an immune oncology signature;

displaying a report, the report comprising an indication that the subject is selected for an immune oncology therapy.

2 . The method of claim 1 , wherein the subject has a cancer that is PD-L1 low, PD-L1 intermediate, or has a low tumor mutational burden.

3 . The method of claim 1 , wherein the one or more machine learning algorithms (MLAs) are trained on training data from a cohort of subjects diagnosed with cancer.

4 . The method of claim 1 , wherein the one or more MLAs comprise a variational autoencoder, an accelerated failure time model, a parametric survival model, a Cox proportional hazards model, a random forest model, a gradient-boosted survival model, a linear model, a recurrent neural network, a transformer neural network, or a convolutional neural network.

5 . The method of claim 1 , wherein the checkpoint related gene signature comprises expression values for one or more genes selected from CD274, SPP1, CXCL9, CD74, CD276, IDO1, PDCD1LG2, and TNFRSF5.

6 . The method of claim 1 , wherein the checkpoint related gene signature comprises expression values for CD274, SPP1, CXCL9, CD74, CD276, IDO1, PDCD1LG2, and TNFRSF5.

7 . The method of claim 1 , wherein the immune exhaustion signature comprises expression values for the following genes TMSB4X, CCL5, TSC22D3, CYTOR, CXCL13, TXNIP, PTPRCAP, RGCC, IGLC3, CYTIP, IGHV1-69D, CXCR4, HMGN2, HSPD1, NEU1, TPD52, GZMB, PIM1, SRGN, BST2, PDE4B, HSPA8, PRF1, CD7, and SLC38A5.

8 . The method of claim 1 , wherein the immune exhaustion signature comprises expression values for one or more genes selected from TMSB4X, CCL5, TSC22D3, CYTOR, CXCL13, TXNIP, PTPRCAP, RGCC, IGLC3, CYTIP, IGHV1-69D, CXCR4, HMGN2, HSPD1, NEU1, TPD52, GZMB, PIM1, SRGN, BST2, PDE4B, HSPA8, PRF1, CD7, SLC38A5, TIFA, DOK2, PPP1R2, DMAC1, DNAJB1, TAGAP, GZMA, CD27, GADD45A, HSPH1, STMN1, GZMH, CLIC3, GLIPR1, CHORDC1, CD3E, CD69, BAG3, ATF3, MICB, TRBC2, EZR, ARHGDIB, CASC8, ITM2A, DDX24, CD52, RAC2, TERF2IP, ELF1, FAM96B, GGH, NKG7, LY6E, CITED2, ZFAND2A, SAMSN1, CST7, CDKN3, TCEAL3, BBC3, IL32, MBD4, DNAJA4, TMEM141, UBB, HCST, IGLV1-40, HOPX, RHOH, USB1, H2AFZ, CSRP1, IKZF1, RGS2, IGLC2, CCND2, SELPLG, FUNDC2, IGFBP7, IGKV3-15, SERPINE2, TRDMT1, RGS1, HMOX1, HSP90AB1, HSPA1A, LIME1, TUBB, MRPL10, IFI44L, COTL1, LBH, ZEB2, HMGB2, LDHA, LGALS3, CYLD, PXMP2, CD74, PPIH, CD8A, RFX2, KLRD1, KLF6, LINC02446, HTRA1, TUBA4A, HSPB1, DNAJA1, CD3D, DUSP2, ELL2, TPM1, CKS1B, LGALS1, BEX3, GLRX, CCL4, GBP5, PTPRC, CLK1, IRF4, PIM2, SAT1, CXCR3, ZFP36, CD24, PELI1, CKS2, GYPC, FOXN2, IGLV1-51, IFT46, IGLV1-41, PLA2G16, COMMD8, IPCEF1, SMPDL3B, EVL, EVI2B, RAB11FIP1, DUSP5, HAVCR2, UBC, CRIP1, SRPRB, SERPINA1, PCSK7, BCL2L11, HSPA6, CWC25, CORO1A, TPST2, MBNL2, CKB, TUBA1B, GABARAPL1, PXDC1, SEL1L, PPP1R8, FKBP4, GABARAPL2, JCHAIN, STK17B, ZWINT, CHMP1B, ID2, HERPUD1, ROCK1, SKAP1, S100A4, CXCL10, CASP3, APOC1, ARID5B, SMAP2, CSRNP1, ADIRF, HLA-DPA1, PPP1R15A, DMKN, SCAF4, MYL9, LYAR, ZBTB25, GADD45B, GCHFR, LINC01588, RAB20, LSP1, FCGR2B, HIST2H2AA4, NCF4, LCK, IGHV3-33, LAPTM5, TUBB4B, TPM2, RBM38, RBP4, CCNA2, SERTAD1, ITM2C, PLPP5, DNAJB9, SYNGR2, TUBB2A, ERLEC1, TMED9, IFI6, HSP90AA1, PTPN1, TTL, DKK1, TM2D3, DCAF11, RIC1, SERPING1, DERL3, KDELR3, GEM, KLF9, TYROBP, CERCAM, CCDC84, ODC1, CYP2C9, CFLAR, HLA-DMB, DUSP1, JSRP1, TRIB1, JUN, NFATC2, EMP3, SNRNP70, TMED5, ST8SIA4, IGLV3-1, ZNF394, TNFSF9, CTSW, CUL1, BACH1, RABL3, KPNA2, EPS8L3, IER5, HSPA1B, CADM1, MCL1, RNF19A, ITGA4, CD38, WIPI1, CENPK, HCLS1, SPICE1, HIST1H2BC, MPRIP, FOSB, SERPINB8, FAM126A, CEP55, ATXN1, VCL, SOCS1, PCNX1, SQOR, JUNB, C10orf90, LCP1, STRADB, CREB3L2, GNG7, CCNH, SNX2, IGSF1, CCNL1, FKBP11, DBF4, ICAM1, MAD2L1, TMEM176B, PAIP2B, CD79A, SRXN1, NOB1, IER2, HLA-DRA, ZFP36L1, MZB1, MAGEA4, JUND, CD8B, AARS, TXNDC15, AC016831.7, GNA15, ATM, TSC22D1, GZMK, RAC3, ZNF263, TNFAIP3, H1FX, FGG, FHL2, MBNL1, TMEM205, IGLV6-57, CD96, TUBA1C, UCHL1, PRDM1, SRPK2, NUP37, TMEM87A, THEMIS2, HSPA5, PCMT1, TUBA1A, IGHG1, ANKRD37, MEF2C, XRN1, POU2AF1, BCL6, INAFM1, ADH4, TGFB1I1, PBK, DCN, FCRL5, DNAJB4, HLA-DQA1, TBC1D23, TMEM39A, GCC2, TMEM192, IGHA1, PTHLH, MFAP5, GEMIN6, BIRC3, IGHV4-4, SLC6A6, CYP2R1, HLA-DRB1, PPP1R15B, HMCES, MYC, WISP2, CHN1, ILK, PXN-AS1, LINC01970, CRIP2, PCOLCE2, MTMR6, EDIL3, AGR2, MEF2B, PFKM, KIAA1671, GLIPR2, SSTR2, SERPINB9, HIST1H1E, PTTG1, WSB1, ERN1, Z93241.1, IGLV1-44, SDS, TLE1, NUPR1, IGLV1-47, ICAM2, NXF1, RSPO3, TCF4, AC243960.1, RARRES2, RMDN3, RBFOX2, SEC11C, OLMALINC, FADS2, ITPRIP, FOS, SFTPD, HAUS3, RNF43, HIST1H4C, TIGAR, BIK, ITGA1, TARSL2, AFP, SNORC, MKLN1, BTG2, KRT18, NOC2L, ZFP36L2, NFKBIA, RHOB, HMGA1, BRD3, IGHJ6, U62317.5, SLC2A3, AC034231.1, CLEC11A, EPCAM, SKI, PNOC, MIR155HG, C12orf75, SAMHD1, IGKV3D-15, ACTN1, GSTZ1, TUBB3, CAV1, OAT, COBLL1, SSR4, ACTA2, HBA1, FAM83D, PLA2G2A, RAB14, AC106791.1, RAB23, AC244090.1, KMT5A, SERPINB1, P3H2, XRCC1, AC106782.1, MAL2, EGR1, F8, PLIN2, SOWAHC, IGFBP6, NFKBIZ, XBP1, SLC25A51, IGHM, KCTD5, USP38, FCER1G, PHLDA1, BYSL, HLA-DRB5, RAPH1, DUSP23, FUOM, ISYNA1, TNK2, STAP2, SLC25A4, GALNT2, SGO2, FHL3, ALB, CYP20A1, TM4SF1, ADA, RRP9, DNAH14, BOLA2, BHLHE41, CCL20, AC005537.1, UBALD2, VGLL4, NUDT1, USP10, ADSSL1, PRSS23, FMC1, ARHGAP45, HSPA14-1, CREB5, RBM33, TMX4, ROCK2, ARSK, PALLD, FNDC3B, FOXA3, BATF, PTP4A3, CDC45, IGHV1-2, IMMP2L, STARD10, HIST2H2BF, MTG2, FBXO8, USP32, ADIPOR2, RRM2, DHODH, DDIT4, NFAT5, PPARG, YTHDF3-AS1, GNG4, CSPP1, UBE2S, ZNF473, TIMP1, CPQ, AOC2, H1F0, JRK, EXOSC9, AC012236.1, AC009403.1, C12orf65, AURKA, MYH9, IGKV4-1, IGHMBP2, JADE1, HIST1H3C, TTC39A, SGMS1, LBP, FRYL, DNAJB2, GNG11, HAGHL, ANXA6, MARS, ADD1, KDM4B, TMEM91, AC008915.2, CXCL14, DUSP14, GJB2, PGM1, ETS2, GNPDA1, COL18A1, KLF10, MT1A, TPX2, S100A2, MAP3K5, HIST1H2AE, SLC20A2, ITGB7, SCEL, RSRP1, AKR1B1, GINS1, ZNF296, ALKBH4, UBE2C, ANKRD36C, SULT2B1, SMC5, TSPYL2, TNS4, TIMP3, ID4, SDC1, COX18, CDC42EP2, SQLE, ZNRF1, AKR1B10, NDC80, GFPT2, MAP1B, HIST1H2AG, IDO1, RNF185, UHRF1BP1, ADORA2B, CALD1, PHLDA2, ADH6, TFAP2A, DLG1, MELK, CBWD3, RAB4B, KANSLIL, RCE1, HIST1H2AC, CDK1, TCIM, C17orf67, BRD4, LY6E-DT, SLC1A6, ARL13B, IRF1, DDX3X, RAB2B, MYBBP1A, ARFGAP1, BOP1, IGKV3D-7, KMT2E-AS1, DTNBP1, LAMC2, ATG4C, MYBL2, LRP10, PALMD, ZBTB4, SYTL2, SERPINH1, CD248, CNEP1R1, FURIN, IGLL5, MEST, MDK, NUP205, NRDE2, ECT2, TENT5A, TNKS1BP1, NFXL1, SLC35E3, ECE1, RASD1, SLC52A2, DCBLD2, CP, POLE, COL27A1, SBNO1, SLC7A6, HYKK, SLPI, CFHR1, SPDEF, DACT2, TUBGCP5, AREG, HIST1H2AJ, KIF2A, AL135925.1, NOTCH3, SLC11A1, HEXIM2, IGFBP1, TVP23A, NUDT14, SAMD11, MIR200CHG, PCLAF, SLC43A3, FAM30A, PHRF1, ADM, SIK2, NUSAP1, CFH, KRTCAP3, SPAG4, TPPP3, TSPAN4, AAK1, CST1, CLU, IFRD1, ASPHD2, CNN3, COL4A1, FGA, ANO6, SBSN, FGB, ATP9B, NLGN4Y, HP, EPS8, RNF111, LINC01285, MAOA, IGHV4-31, TNFRSF10D, GSR, IGHGP, TACSTD2, MT1F, RHCG, MUT, PI3, MT1M, LAMB3, MTRNR2L12, SLC35A2, DDX10, RARRES1, MTSS1, CLK2, RPN2, MED29, CYP1B1, TTTY14, DMXL1, AL139246.5, TAF1, DAAM1, MYO1E, MAFB, CDKN1A, F8A3, FABP5, CFB, HSP90B1, SGK3, HMG20B, CDCA5, CLDN4, SYNM, PAWR, TWNK, AC116049.2, RND3, ATP11A, PID1, MALAT1, TMEM168, TFF1, TFRC, RNASET2, SPINK13, PABPC1L, P4HA2, PRSS8, SPINT1, MSC, FMNL1, SLC8B1, UNC13D, SPINT2, DCP1A, NPTN, IGKV3D-11, G6PD, KRT6A, LYPD1, TESC, COL4A2, ELF3, BCAM, AC093323.1, IGHV1-69, LINC00511, PORCN, TPRG1-AS1, EFNB2, PARD6G-AS1, CD9, RGS16, IL6R, FZD3, GLYR1, B3GALT6, LRCH3, MAFK, LINC00491, MT1X, MUC6, PIK3R3, GBP4, PERP, LXN, ZBTB7A, WARS, AC020911.2, MAPK3, ALS2CL, MRE11, TSPAN17, IGHV4-34, IL33, ADAM9, ANGPTL4, TBC1D31, C1R, CTSC, SLC35A4, FST, SGO1, ANKRD36, IGHG3, SLC15A3, HES1, POLR1E, SLC7A5, CAPN12, IGFBP3, FBXO38, FLNA, CSKMT, OAS1, ULK1, PBX1, EXOC4, REEP6, HILPDA, ASF1B, FKBP1B, IL6, CALU, AKR1C1, KLF2, GRTP1, C1S, SMOX, CPLX2, LMNA, BSG, IGHG4, SVIL, HIST1HIB, GCH1, NEAT1, FN1, ESRP1, RFWD3, ADGRE2, SPINK6, HPD, CAVIN1, MT1E, CLDN10, C15orf48, CA9, NR4A1, PPP1R3B, SLC30A1, SLC7A11, VIRMA, NAA25, CCNB1, CFD, AP1G1, H6PD, PSCA, KCNK6, AL161431.1, DVL1, HIST1H2AM, RAB31, CDCA3, SPATA20, PRMT7, PTGR1, SERINC2, IGHG2, GFPT1, TTC22, BTBD1, HIST1H4H, CENPB, ZNF598, GPATCH2L, SPTLC3, CXCL2, CYP24A1, EZH2, GPX2, LMNB2, PTGES, MGLL, NR2F2, KRT19, DNTTIP1, MUC5AC, SDCBP2, IL1R2, AHNAK2, MUC16, AC023090.1, CPE, VNN1, BAMBI, NPW, TK1, IGKV3D-20, ANKRD11, CDC20, CDH1, STK11, IGKC, SLC45A4, TBC1D8, CSTA, AC233755.1, MIGA1, HIST1H2AL, AKAP12, MAP4K4, HOOK2, GGA3, COL7A1, NOS1, ARHGAP26, AKR1C2, TGM2, CENPF, IGHV3-48, CDCA8, TSC2, STC2, PKN3, PVR, CES1, GPRC5A, SEZ6L2, CEP170B, KIF14, IER3, ALDH3B1, TOP2A, SPP1, TXNRD1, LENG8, TRIM15, ALDH3A1, RIMKLB, HECTD4, SMOC1, NEB, RMRP, IGFBP4, MT1G, SCRIB, ERO1A, SOX4, LMO7, RNPEPL1, PLK2, COL6A2, FLRT3, IGHV4-28, SCD, KRT7, PIEZO1, CXCL1, DAPK1, ID1, C3, CXCL3, IGKV3-20, GUCA2B, ITGA3, SFN, IGLV3-21, PLEC, POLR2A, AGRN, MUC1, SERPINB3, S100A8, LAMA5, COL6A1, ITGB4, S100P, SLURP2, MSLN, KRT17, and MUC5B.

9 . The method of claim 1 , wherein the gMDSC signature comprises expression values for one or more genes selected from SERPINB1, SOD2, S100A8, CTSC, CCL18, CXCL2, PLAUR, NCF2, FPR1, and IL8.

10 . The method of claim 1 , wherein the gMDSC signature comprises expression values for one or more genes selected from SERPINB1, SOD2, S100A8, CTSC, CCL18, CXCL2, PLAUR, NCF2, FPR1, IL8, S100A9, TNFAIP3, CXCL1, BCL2A1, EMR2, LILRB3, SLC11A1, IL6, TREM1, CCL20, LYN, CXCL3, IL1B, IL1R2, AQP9, IL2RA, GPR97, OSM, CXCR1, FPR2, C19orf59, CXCR2, CXCL6, CXCL5, EMR3, MEFV, S100A12, CD300E, FCGR3B, PPBP, LILRA5, LILRA3, and CASP5.

11 . The method of claim 1 , wherein the immune oncology (IO) signature comprises expression values for one or more genes selected from GBP5, IL10RA, NLRC5, CXCL9, RAC2, GBP4, GLUL, IRF1, CD53, CIITA, S100B, GBP2, ITK, SLAMF7, IKZF3, DOCK2, SELL, ARHGAP9, CYTIP, IL2RB, NCKAP1L, APOD, CD96, IL7R, and ZAP70.

12 . The method of claim 1 , wherein the immune oncology (IO) signature comprises expression values for one or more genes selected from ISG20, PCDHGA2, TGFB1I1, ATP8B1, IL7R, IRF8, ETV1, MYLK, GRHL2, THBS4, CYP3A5, FBLIM1, S100B, BICD1, SLAMF7, RAB27A, GATM, ICA1, ITPR1, SLC7A2, ZAP70, LOXL4, CILP, ARHGAP30, ITGB2, KLF5, PRKCA, PCDH7, DPYSL3, RGS2, SPP1, COLGALT2, MPZL2, TNFAIP8, PLAT, ALDH1A3, POF1B, PPP1R9A, SEMA3A, CIITA, DLC1, ARHGAP9, FRAS1, AKAP6, ATP1A2, TTN, LTBP1, NCKAP1L, MAP3K6, MYO1B, MRVI1, FSCN1, GPC1, GBP5, BAMBI, IL2RB, MYO1G, RANBP17, APOD, RASGRP1, CYTIP, ITGA7, CYTH4, PTPRF, KIAA1755, IRF1, GPR37, RAC2, NLRC5, EGFR, ITK, IL10RA, IGFBP2, CD96, RASD1, CD36, TMEM163, IGLL5, IKZF3, PRLR, CDC42BPG, DOCK2, PAM, VEGFA, CD84, SORL1, GBP2, SYTL4, APBB1IP, SIGLEC10, GBP4, COMP, DOCK8, CXCL9, NRP1, EPHB4, CD53, GLUL, DNM1, DSP, SIX4, SELL, DSC3, TNFAIP2, and JAG2.

13 . The method of claim 1 , wherein the TMB is derived from the DNA sequencing data.

14 . The method of claim 1 , wherein the expression values of the checkpoint related gene signature, the immune exhaustion signature, and the granulocytic myeloid derived suppressor cell (gMDSC) signature are derived from the RNA seq data.

15 . The method of claim 1 , wherein the IO therapy is an immune checkpoint inhibitor therapy (ICI).

16 . The method of claim 15 , wherein the ICI comprises pembrolizumab or nivolumab.

17 . The method of claim 1 , wherein the report further comprises an immune profile score (IPS).

18 . The method of claim 17 , wherein the IPS is displayed as an integer from 1-100.

19 . The method of claim 17 , wherein the IPS is further divided into categories or is a categorical result.

20 . The method of claim 19 , wherein the categories are IPS-Low, indeterminate, and IPS-High.